Plantina has been acquired by Nutramin
E. de Groot and G. Schuitemaker, private shareholders of Plantina, have sold the company to Nutramin.
Plantina is a developer and supplier of branded food supplements primarily for the Dutch market and, to a lesser extent, for the Belgian and German markets. The company's products are marketed under the strong and renowned Plantina brand and Performax in Germany. The Plantina brand is known for its superior quality and effectiveness due to its choice of raw materials and suppliers, and its relative high dosing.
Founded in 1982, Nutramin is a developer and supplier of food supplements with a focus on healthcare professionals, doctors and therapists. Additionally, the company provides informative services such as conferences in congresses, master classes and training sessions which highlight its academic and professional background.
Oaklins' team in the Netherlands advised the seller in this transaction.
Talk to the deal team
Related deals
Instituto Sanitas and Chemopharma have been acquired by Laboratorios Saval
Instituto Sanitas and Chemopharma, leading pharmaceutical laboratories in Chile, have been acquired by Laboratorios Saval S.A., a prominent pharmaceutical company based in Chile with a regional presence across Latin America. The transaction strengthens Laboratorios Saval’s growth strategy and supports its expansion in the affordable medicines segment.
Learn moreRare Patient Voice has been acquired by Konovo
Rare Patient Voice has been acquired by Konovo, a technology-first healthcare intelligence company backed by Fraser Healthcare Partners.
Learn moreLindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn more